Loading clinical trials...

Basiliximab in Moderate to Severe Ulcerative Colitis | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT00430898

Basiliximab in Moderate to Severe Ulcerative Colitis

The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.

Lead sponsor: Cerimon Pharmaceuticals•25 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 4

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

NCT07550673 · Acute Severe Ulcerative Colitis

RECRUITING

Association Between LRG and Histologic Remission in Ulcerative Colitis

NCT06372613 · Ulcerative Colitis in Histologic Remission

RECRUITINGPhase 1/2

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07374471 · Ulcerative Colitis (UC)

RECRUITINGPhase 1/2

Superdonor FMT in Patients With Ulcerative Colitis

NCT05739864 · Active Ulcerative Colitis

RECRUITINGPhase 1/2

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

NCT06071312 · Clostridium Difficile, Ulcerative Colitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 18, 2008Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment181

Start dateJan 2007

Last updatedDec 18, 2008

Condition

Ulcerative Colitis

Locations shown

Anaheim, California

Roseville, California

Golden, Colorado

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2008Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Basiliximab in Moderate to Severe Ulcerative Colitis

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

Association Between LRG and Histologic Remission in Ulcerative Colitis

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

Superdonor FMT in Patients With Ulcerative Colitis

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

Trial snapshot

Condition

Locations shown

For caregivers